|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||December 01, 2008|
|Effective date (End):||October 31, 2009|
|Field of knowledge:||Physical Sciences and Mathematics - Chemistry - Inorganic Chemistry|
|Principal Investigator:||Roberto Santana da Silva|
|Grantee:||Ana Carolina Lemos Prazias|
|Home Institution:||Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil|
Nitric oxide is radical specie involved in several different biological processes. In despite the great importance of NO in biological system studies involved its pharmacological properties are limited, mainly due its reactivity and short lifetime. So, the development of new compounds capable to release NO could be an alternative to solve this problem and maybe an useful tool for therapeutic applications. Nitroprusside is an NO donor agent used as a drug in clinical therapy, mainly in angin treatment. Due its chemical structure nitroprusside releases NO and also cyanide, which is toxic to biological system. Furthermore the nitroprusside (SNP) toxic effects some nitrosyl metal complexes have been studied as new NO donor agents. Among them cis-[RuCl(dcbpy)2(NO)]2+ onde dcbpy é 2,2'-bipyridine-4,4'-carboxilic acid. This complex was synthesized by prof. Roberto Santana da Silva and shows vasodilation properties similar to SNP. This compound also show tumorigenical activities against melanoma cancer cells B16F10. Although this properties complete metabolism studies in vitro and in vitro should be developed, in order to develop new metal base drug. In vitro studies represent the first step to find the metabolites originated from the administration of this complex. So, this project will involve the metabolism elucidation of cis-[RuCl(dcbpy)2(NO)]2+ free or associated to a fotosensitizer. HPLC and mass spectrometry will used to find and understand the metabolization of those species.